Table 1 Demographic and clinical characteristics of patients with HCC treated with TACE
Baseline characteristic | n = 98, (%) or median, (range) |
|---|---|
Age, years | 71 (33–84) |
Gender | |
Male | 76 (78) |
Female | 22 (25) |
Risk factors for Chronic Liver Disease | |
Hepatitis C Virus infection | 32 (33) |
Hepatitis B Virus Infection | 12 (12) |
Ethanol Excess | 38 (39) |
Others | 9 (9) |
Unknown | 8 (8) |
Child Turcotte Pugh Class | |
A | 76 (77) |
B | 22 (23) |
BCLC Stage | |
A | 10 (10) |
B | 77 (78) |
C | 11 (11) |
Number of Nodules | |
1–2 | 77 (79) |
> 2 | 21 (21) |
Maximum tumour diameter | |
≤ 7 cm | 71 (72) |
> 7 cm | 27 (28) |
Portal vein invasion (PVI) | |
Absent | 87 (89) |
Present | 11 (11) |
Albumin, g/L | 33 (14–47) |
Total bilirubin, umol/L | 17 (4–124) |
ALT, IU/L | 44 (10–348) |
AST, IU/L | 59 (20–999) |
ALP, IU/L | 207 (62–680) |
AFP, ng/ml | 45 (2–130.000) |
INR | 1.1 (1.0–1.4) |
Platelet Count, × 109/L | 133 (46–444) |
Number of TACE procedures | |
1 | 33 (34) |
2 | 33 (34) |
≥ 3 | 32 (32) |
Prior Treatments | |
First line TACE | 78 (79) |
Resection | 7 (6) |
Transplantation | 1 (1) |
Radiofrequency ablation | 22 (14) |
Modified RECIST response following TACE | |
Complete Response | 15 (15) |
Partial Response | 28 (29) |
Stable Disease | 36 (37) |
Progressive Disease | 7 (7) |
Missing | 12 (12) |
Peri-tumoural capsule (PTC) | |
Absent | 81 (83) |
Present | 17 (17) |
Ectatic arterial neovascularization (EAN) | |
Absent | 10 (10) |
Present | 88 (88) |
Artero-venous shunting (AVS) | |
Absent | 47 (48) |
Present | 48 (49) |
Not assessable | 3 (3) |
Intra-tumour necrosis (ITN) | |
< 50% | 89 (90) |
> 50% | 9 (10) |